Up and down the growth hormone cascade

Cytokine and Growth Factor Reviews

Volumn 7, Issue 1, 1996, Pages 65-80

  Clark, Ross G ^a   Robinson, Iain CAF ^b  

^a GENENTECH INC   (United States)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

Diabetes; Differential effects of GH; Fat vs lean body mass; GH binding proteins (GHBPs); GH Receptors; GH releasing peptides (GHRPs); GH secretagogues; Growth hormone (GH); Hypothalamic control of GH; IGF Binding Proteins (IGFBPs); IGF Receptors; Immune System; Insulin like growth factor 1 (IGF 1)

Indexed keywords

3 (2 HYDROXYPROPYLAMINO) 3 METHYL N [2,3,4,5 TETRAHYDRO 2 OXO 1 [[2' (1H TETRAZOL 5 YL) 1,1' BIPHENYL 4 YL]METHYL] 1H 1 BENZAZEPIN 3 YL]BUTANAMIDE; 3 AMINO 3 METHYL N [2,3,4,5 TETRAHYDRO 2 OXO 1 [[2' (1H TETRAZOL 5 YL) 1,1' BIPHENYL 4 YL]METHYL] 1H 1 BENZAZEPIN 3 YL]BUTANAMIDE; CARRIER PROTEIN; GROWTH HORMONE; GROWTH HORMONE BINDING PROTEIN; GROWTH HORMONE RECEPTOR; GROWTH HORMONE RELEASING FACTOR; HEXARELIN; HUMAN GROWTH HORMONE; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C;

ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; BLOOD; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ANTAGONISM; FEEDBACK SYSTEM; GENETIC ENGINEERING; GLUCOSE METABOLISM; GROWTH HORMONE RELEASE; GROWTH REGULATION; HORMONE RECEPTOR INTERACTION; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNE SYSTEM; LIGAND BINDING; METABOLIC REGULATION; MOUSE; NONHUMAN; PHYSIOLOGY; POSTNATAL DEVELOPMENT; RAT; RECEPTOR BINDING; REVIEW; TRANSGENIC MOUSE;

EID: 0030183045     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/1359-6101(96)00006-8     Document Type: Short Survey

References (128)

1. 1. Frohman LA, Downs TR, Chomczynski P. Regulation of growth-hormone secretion. Front Neuroendocrinol 1992, 13, 344-405.
2. 2. Thomas GB, Cummins JT, Francis H, Sudbury AW, McCloud PI, Clarke IJ. Effect of restricted feeding on the relationship between hypophysial portal concentrations of growth hormone (GH)-releasing factor and somatostatin, and jugular concentrations of GH in ovariectomized ewes. Endocrinology 1991, 128, 1151-1158.
3. 3. Eicher EM, Beamer WG. Inherited ateliotic dwarfism in mice: characteristics of the mutation little on chromosome 6. J Hered 1976, 67, 87-91.
4. 4. Clark RG, Robinson ICAF. Effect of a fragment of human growth hormone-releasing factor in normal and 'little' mice. J Endocrinol 1985, 106, 1-5.
5. 5. Jansson JO, Downs TR, Beamer WG, Frohman LA. Receptor-associated resistance to growth hormone-releasing hormone in dwarf 'little' mice. Science 1986, 232, 511-513.
6. 6. Godfrey P, Rahal J, Beamer W, Copeland N, Jenkins N, Mayo K. GHRH receptor of little mice contains a missense mutation in the extracellular domain that disrupts receptor function. Nature Genet 1993, 4, 227-232.
7. 7. Lin S-C, Lin C, Gukovsky I, Lusis A, Sawchenko P, Rosenfeld M. Molecular basis of the little mouse phenotype and implications for cell-type specific growth. Nature 1993, 364, 208-213.
8. 8. Struthers RS, Vale WW, Arias C, Sawchenko PE, Montminy MR. Somatotroph hypoplasia and dwarfism in transgenic mice expressing a non-phosphorylatable CREB mutant. Nature 1991, 350, 622-694.
9. 9. Burton FH, Hasel KW, Bloom FE, Sutcliffe JG. Pituitary hyperplasia and gigantism in mice caused by a cholera toxin transgene. Nature 1991, 350, 74-77.
10. 10. Frohman LA, Downs TR, Kashio Y, Brinster RL. Tissue distribution and molecular heterogeneity of human growth hormone-releasing factor in the transgenic mouse. Endocrinology 1990, 127, 2149-2156.
11. 11. Stefaneanu L, Kovacs K, Horvath E, et al. Adenohypophysial changes in mice transgenic for human growth hormone-releasing factor - a histological, immunocytochemical, and electron microscopic investigation. Endocrinology 1989, 125, 2710-2718.
12. 12. Vallar L, Spada A, Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 1987, 330, 566-568.
13. 13. Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest 1989, 83, 1533-1540.
14. 14. Felix AM, Lu YA, Campbell RM. Pegylated peptides 4. Enhanced biological-activity of site-directed pegylated GRF analogs. Int J Peptide Protein Res 1995, 46, 253-264.
15. 15. Carrick TA, Bingham B, Eppler CM, Baumbach WR, Zysk JR. A rapid and sensitive binding assay for growth-hormone releasing-factor. Endocrinology 1995, 136, 4701-4704.
16. 16. Thorner MO, Vance ML, Rogol AD. et al. Growth hormone-releasing hormone and growth hormone-releasing peptide as potential therapeutic modalities. Acta Paediatr Scand Suppl 1990, 367, 29-32.
17. 17. Spengler D, Waeber C, Pantaloni C, et al. Differential signal transduction by five splice variants of the PACAP receptor. Nature 1993, 365, 170-175.
18. 18. Chadwick DJ. Cardew G. eds (1995). Somatostatin and its receptors. Ciba Foundation Symposium Series, Vol. 190. Chichester, John Wiley, 1995, 274.
19. 19. Bruno JF, Xu Y, Song JF, Berelowitz M. Tissue distribution of somatostatin receptor subtype messenger-ribonucleic acid in the rat. Endocrinology 1993, 133, 2561-2567.
20. 20. Day R, Dong WJ, Panetta R, Kraicer J, Greenwood MT, Patel YC. Expression of messenger-RNA for somatostatin receptor (sstr) type-2 and type-5 in individual, rat pituitary-cells - a double-labelling in situ hybridization analysis. Endocrinology 1995, 136, 5232-5235.
21. 21. Reisine T, Woulfe D, Raynor K, et al. Interaction of somatostatin receptors with G proteins and cellular effector systems. In Chadwick DJ, Cardew G, eds. Ciba Foundation Synposium Series, Vol. 190. Chichester, John Wiley, 1995, 160-167.
22. 22. Berelowitz M. The somatostatin receptor - a window of therapeutic opportunity. Endocrinology 1995, 136, 3695-3697.
23. 23. Lamberts S, Hofland LJ, Deherder WW, Kwekkeboom DJ, Reubi JC, Krenning EP. Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphy. Front Neuroendocrinol 1993, 14, 27-55.
24. 24. Clark RG, Carlsson LMS, Rafferty B, Robinson ICAF. The rebound release of growth hormone (GH) following somatostatin infusion in rats involves hypothalamic GH-releasing factor release. J Endocrinol 1988, 119, 397-404.
25. 25. Miki N. Ono M, Shizume K. Withdrawal of endogenous somatostatin induces secretion of growth hormone-releasing factor in rats. J Endocrinol 1988, 117, 245-252.
26. 26. Epelbaum J, Moyse E, Tannenbaum GS, Kordon C Beaudet A. Combined autoradiographic and immunohistochemical evidence for an association of somatoslatin binding sites with growth hormone-releasing factor-containing nerve cell bodies in the rat arcuate nucleus. J Neuroemdocrinol 1989, 1, 109-115
27. 27. Willoughby J, Brogan M, Kapoor R, Hynothaiamic interconnections of somatostatin and growth hormone releasing factor on growth hormone secretion. Neuroendocrinology 1989, 50, 584-591.
28. 28. Mellon PL, Wetsel WC, Windle JJ, et al. Immortalized hypothalamic gonadotropin-releasing hormone neurones. In Chadwick DJ, Marsh J, eds. Ciba Fooundation Symposium Series, Vol. 160. Chichester. John Wiley. 1942, 104-117.
29. 29. Holiingshead P. Martin L. Pitts S. Stewart T. A dominant phenocopy of hypopituitarism in transgenic mice resulting from central nervous system synthesis of human growth hormone. Endocrinology 1989, 125, 1556-1564.
30. 30. Flavell D, Wells T, Wells SE. Carmignac DF, Thomas GB, Robinson ICAF. A new dwarf rat. I - Dominant negative phenotype in GRF-GH transgenic growth retarded (Tgr) rats. Proc 77th Ann Mtg Endocrine So; 1995, P2-239.
31. 31. Lobie PE, GarciaAragon J, Lincoln DT, Barnard R, Wilcox JN, Waters MJ. Localization and ontogeny of growth hormone receptor gene expression in the central nervous system. Derl Brain Res 1993, 74, 225-233.
32. 32. Bennett PA, Levy A, Sophokleous S, Robinson ICAF. Lightman SL. Hypothalamic GH receptor gene expression in the rat: effects of altered GH status. J Endocrinol 1998, 147, 225-234.
33. 33. Burton KA, Kabigting EB, Clifton DK, Steiner RN. Growth hormone receptor messenger RNA distribution in the adult male rat brain and its co-localization in the hypothalamic somatostatin neurons. Endocrinology 1992, 131, 958-963.
34. 34. Yamashita S. Melmed S. Insulin-like growth factor I action on rat anterior pituitary cells: suppression of growth hormone secretion and messenger ribonucleic acid levels. Endocrinology 1986, 118, 176-182.
35. 35. Baumbach WR, Bingham B. One class of growth hormone (GH) receptor and binding protein messenger ribonucleic acid in rat liver. GHR1, is sexually dimorphic and regulated by GH. Endocrinology 1995, 136, 749-760.
36. 36. Gabrielsson BG, Carmignac DF, Flavell DM, Robinson ICAF. Steroid regulation of growth hormone (GH) receptor and GH-binding protein messenger ribonucleic acids in the rat. Endocrinology 1995, 136, 209-217.
37. 37. Bowers CY, Momany F, Chang D, Hong A, Chang K. Structure-activity relationships of a synthetic pentapeptide that specifically releases GH in vitro. Endocrinology 1980, 106, 663-667.
38. 38. Bowers CY, Momany F, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeplide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984, 114, 1537-1545.
39. 39. Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumour that caused acromegaly. Science 1982, 218, 585-587.
40. 40. Rivier J, Spiess J, Thorner MO, Vale WW. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature 1982, 300, 276-278.
41. 41. Clark RG, Carlsson LMS, Trojnar J, Robinson ICAF. The effects of a growth hormone-releasing peptide and growth hormone-releasing factor in conscious and anesthetized rats. J Neuroendocrinol 1989. 1, 249-255.
42. 42. Bowers CY. Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endoccrinol Wetab 1990. 70, 975-982.
43. 43. Hartman ML, Farello G, Pezzoli SS, Thorner MO. Oral administration of growth-hormone (GH)-releasing peptide stimulates GH secretion in normal men. J Clin Endoccrinol Metab 1992, 74, 1378-1384.
44. 44. Deghenghi R. Cananzi MM, Torsello A, Battisti C, Muller EE, Locatelli V. GH-releasing activity of hexarefin, a new growth hormone releasing pentide, in infant and adult rats. Life Sci 1994, 54, 1321-1328.
45. 45. Bowers CY. GH releasing peptides -structure and kinetics. J Paed Endocrinol 1993, 6, 21-31.
46. 46. Smith RG, Cheng K, Schoen WR, et al. A nonpeptidyl growth hormone secretagogue. Science 1993, 260, 1340-1343.
47. 47. McDowell RS, Ilias KA, Stanley MS, et al. Growth hormone secretagogues: characterization. efficacy and mininval bioactive conformation. Proc Natl Acad Sci USA 1995, 92, 11165-11169.
48. 48. Patchett AA. Nargund RP, Tata JR. et al. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci USA 1995, 92, 7001-7005.
49. 49. Codd EF, Shu AYL, Walker RF. Binding of a growth hormone releasing hexapeptide to specific hypothalamic and pituitary binding sites. Neuropharmacology 1989, 28, 1139-1144.
50. 50. Veraragavan K, Sethumadhavan K,Bowers CY. Growth hormone-releasing peptide (GHRP) binding to porsine anterior pituitary and hypotalamic membranes. Life Sci 1992, 50, 1149-1155.
51. 51. Bitar KG, Bowers CY, Coy DH. Effect of substance P bombesim antagonist on the release of growth hormone by GHRP and GHRH. Biochem, Biophys Res Commun 1991. 180, 156-161.
52. 52. Bowers CY, Sartor AO, Reynolds GA, Badger TM. On the actions of the growth hormone-releasing hexapeptide. GHRP. Endocrenology 1991, 128, 2027-2035.
53. 53. Cheng K, Chan W, Butler B, et al. Stimulation of growth hormone release from rat primary pituitary cells by L-692.429, a novel non-peptidyl GH secretagogue. Endocrenology 1993, 132, 2729-2731.
54. 54. Hickey G, Drisko J, Faidley T, et al. Mediation by the central nervous system is critical to the in vivo activity of the GH secretagogue L-692.585. J Endocrenol 1996, 148, 371-380.
55. 55. Dickson SL, Leng G, Robinson ICAF. Systemic administration of growth hormone-releasing peptide activates hypothalamic arcuate neurons. Neuroscience 1993, 53, 303-306.
56. 56. Guiliaume V, Magnan E, Cataldi M, et al. Growth-hormone (GH)-releasing hormone-secretion is stimulated by a new GH-releasing hexapeptide in sheep. Endocrinology 1994, 135, 1073-1076.
57. 57. Bowers CY, Veeraragavan K, Sethumadhavan K. A typical growth hormone releasing peptides. In Bereu BB, Walker RF, eds. Growth Hormone II: Basic and Clinical Aspects. New York, Seronon Symposia. 1994, 203-222.
58. 58. Dickson SL, Doutrelant-Viltart O, Leng G. GH-deficient dw dw rats and lit/lit mice show increased Fos expression in the hypothalamic arcuate nucleus following systemic injection of GH-releasing peptide-6. J Endocrinol 1996, 146, 519-526.
59. 59. Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva F. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. J Clin Endocrinol Metab 1995. 80, 942-947.
60. 60. Cordido F, Penalva A, Dieguez C, Casanueva FF. Massive growth-hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6 - evidence for a marked somatotroph secretory capability in obesity. J Clin Endocrinol Metab 1993, 76, 819-823.
61. 61. Chihara K, Kaji H, Hayashi S, et al. Growth hormone releasing hexapeptide: basic research and clinical application. In Bercu BB, Walker RF, eds. Growth Hormone II: Basic and Clinical Aspects, New York. Seronon Symposia. 1994, 223-230.
62. 62. Frieboes R-M, Murck H, Maier P. Schier T, Holsboer F. Steiger A. Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. Neuroendocrinology 1995, 61, 584-589.
63. 63. Elias KA, Ingle GS, Burnier JP, et al. In vitro characterization of four novel classes of GH-releasing peptide. Endocrinoloyy 1995, 136, 5694-5699.
64. 64. Walker RF, Yang SW, Bercu BB. Robust growth-hormone (GH) secretion in aged female rats co-administered GH-releasing hexapeptide (GHRP-6) and GH-releasing hormone (GHRH). Life Sci 1991, 49, 1499-1504.
65. 65. Wells T, Flavell DM, Wells SE. Carmignac DF, Robinson ICAF. A new dwarf rat. II: GH secretion, responses to GRF and somatostatin and growth stimulation by GRF in the GRF GH transgenic (Tgr) rat. Proc 77th Ann Mtg Endocrine Soc 1995, P2-240.
66. 66. Huhn WC. Hartman ML, Pezzoli SS, Thorner MO. 24-Hour growth-hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus. J Clin Endocrinol Metab 1993, 76, 1202-1208.
67. 67. Fairhall KM, Mynett A, Smith RG. Robinson ICAF. Consistent GH responses to repeated injection of GHRP-6 and a new, non-peptide GH secretagogue. L692.5H5. J Endocrinol 1994, 145, 417-426.
68. 2 stimulate growth hormone release through distinct receptor sites. J Endocrinol 1991, 129, 11-19.
69. 69. Leung DW, Spencer SA, Cachianes G, et al. Growth hormone receptor and serum binding protein: puritication. cloning and expression. Nature 1987, 330, 537-543.
70. 70. Wells J, Cunningham B, Fun G, et al. The molecular basis for growth hormone receptor interactions. Rec Prog Horm Res 1993, 48, 253-275.
71. 71. Heldin HC. Dimerization of cell surface receptors in signal transduction. Cell 1995, 80, 213-223.
72. 72. Campbell GS, Christian LJ, CarterSu C. Evidence for involvement of the growth hormone receptor-associated tyrosine kinase in actions of growth hormone. J Biol Chem 1993, 268, 7427-7434.
73. 73. Argetsinger LS, Campbell GS, Yang X, et al. Identification of JAK2 as a growth hormone receptor-associated tvrosine kinase. Cell 1993, 74, 237-244.
74. 74. Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signals. Science 1994, 264, 1415-1421.
75. 75. Bass SH, Mulkerrin MG, Wells JA. A systematic mutational analysis of hormone-binding determinants in the human growth-hormone receptor. Proc Natl Acad Sci USA 1991, 88, 4498-4502.
76. 76. Lowman HB, Wells JA. Affinity maturation of human growth hormone by monovalent phage display. J Mol Biol 1993, 234, 564-578.
77. 77. Cunningham, BC, Wells JA. Rational design of receptor-specific variants of human growth hormone. Proc Natl Acad Sci USA 1991, 88, 3407-3411.
78. 78. Amselem S, Duquesnoy P, Duriez B, et al. Spectrum of growth hormone receptor mutations and associated haplotypes in Laron syndrome. Hum Mol Genet 1993, 2, 355-359.
79. 79. Goddard AD, Covello R, Luoh SM. et al. Mutations of the growth-hormone receptor in children with idiopathic short stature. New Engl J Med 1995, 333, 1093-1098.
80. 80. Wells JA. Structural and functional basis for hormone-binding and receptor oligomerization. Curr Opin Cell Biol 1994, 6, 163-173.
81. 81. Cunningham BC, Ultsch M, Devos AM, Mulkerrin MG, Clauser KR. Wells JA. Dimerization of the extracellular domain of the human growth-hormone receptor by a single hormone molecule. Science 1991, 254, 821-825.
82. 52. Hondo M, Damholt A, Cunningham B, Wells J, De Meyts P, Shymko R. Receptor dimerization determines the effects of growth hormone in primary rat adipocytes and cultured human IM-9 lymphocytes. Endocrinology 1994, 134, 2397-2403.
83. 53. Lobie PE, Wood T. Sliva D. et al. The cellular mechanism of growth hormone signal transduction. Acta Paediatr Suppl 1994, 83, 39-47.
84. 84. Chen WY, Chen NY, Yun J, Wagner TE, Kopchick JJ. In vitro and in vivo studies of antagonistic effects of human growth-hormone analogs. J Biol Chem 1994, 269, 15892-15897.
85. 85. Mode A, Tollet P, Wells T, et al. The human growth hormone (hGH) antagonist G120R hGH does not antagonize GH in the rat, but has paradoxical agonist activity, probably via the prolactin receptor. Endocrinology 1996, 137, 447-454.
86. 86. Robinson ICAF, Clark RG. The secretory pattern of GH and its significance for growth in the rat. In Isaksson OGP, Binder K, Hall B, Hokfelt TC, eds. Growth Hormone: Basic and Clinical Aspects. Amsterdam, Elsevier, 1987, 109-127.
87. 87. Robinson ICAF, Carmignac DF, Fairhall KM. Growth-hormone (GH) receptors, GH binding-protein and GH an autoregulatory system. Acta Paediatr Suppl 1993, 82, 22-28.
88. 88. Maiter D, Underwood LE, Maes M, Davenport ML, Ketelslegers JM. Different effects of intermittent and continuous growth hormone (GH) administration on serum somatomedin-C insulin-like growth factor I and liver GH receptors in hypophysectomized rats. Endocrinology 1988, 123, 1053-1059.
89. 89. Gevers EF. Wit J-M, Robinson ICAF. Growth, growth hormone (GH)-binding protein and GH receptors are differentially regulated by peak and trough components of the GH secretory pattern in the rat. Endocrinology 1996, 137, 1013-1018.
90. 90. Waxman DJ, Ram PA. Park SH, Choi HK. Intermittent plasma growth hormone triggers tyrosine phosphorylation and nuclear translocation of a liver-expressed Stat-5-related DNA binding protein. J Biol Chem 1995, 270, 13262-13270.
91. 91. Trivedi B, Daughaday WH. Release of growth hormone binding protein from IM-9 lymphocytes by endopeptidase is dependent on sulphydryl group inactivation. Endocrinology 1988, 123, 2201-2206.
92. 92. Smith W, Kuniyoshi J, Talamantes F. Mouse serum growth hormone (GH) binding protein has GH receptor extracellular and substituted transmembrane domains. Mol Endocrinol 1989. 6, 984-990.
93. 93. Sadeghi H, Wang BS, Lumanglas AL, Logan JS, Baumbach WR. Identification of the origin of the growth hormone-bonding protein in rat serum. Mol Endocrinol 1990, 4, 1799-1805.
94. 94. Baumann G, Amburn K, Buchanan T. The effect of circulating growth-hormone-binding protein on metabolic clearance, distribution, and degradation of human growth hormone. J Clin Endocrinol Metab 1987, 64, 657-660.
95. 95. Clark R, Cunningham B, Moore J, et al. Growth hormone binding protein enhances the growth promoting activity of GH in the rat. Proc 73rd US Endocrine Mtg Washington Abstr. 1611, 1991.
96. 96. Rosenbloom AL, Savage MO, Blum WF, Guevaraaguirre J, Rosenfeld RG. Clinical and biochemical characteristics of growth-hormone receptor deficiency (Laron syndrome). Acta Paediatr 1992, 81, 121-124.
97. 97. Savage MO, Carlsson L, Chatelain PG, Ranke MB, Rosenfeld RG. Growth-hormone insensitivity syndromes. Acta Paediatr 1995, 84, 87-90.
98. 98. Rieu M, Le Bouc Y, Villares SM, Postel-Vinay MC. Familial short stature with very high levels of growth hormone binding protein. J Clin Endocrinol Metab 1993, 76, 857-860.
99. 99. Buchanan CR, Maheshwari HG, Norman MR, Morrell DJ, Preece MA. Laron-type dwarfism with apparently normal high-affinity serum growth hormone-binding protein. Clin Endocrinol 1991, 35, 179-185.
100. 100. Greene H, Morikawa M, Nixon T. A dual effector theory of growth hormone action. Differentiation 1985, 29, 195-198.
101. 101. Isaksson OGP, Eden S, Jansson J-O. Mode of action of pituitary growth hormone on target cells. Ann Rev Physiol 1985, 47, 483-499.
102. 102. Clark RG, Carlsson LMS, Mortensen DL, Cronin MJ. Additive effects on body growth on insulin-like growth factor-1 and growth hormone in hypophysectomized rats. Endocrinol Metab 1994, 1, 49-54.
103. 103. Fielder PJ, Mortensen DL, Mallet P, Carlsson L, Baxter RC, Clarke RG. Differential long-term effects of IGF-1. GH, and IGF-1 plus GH at body growth and IGF binding proteins in hypophysectomized rats. Endocrinology 1996, 137, 1913-1920.
104. 104. Bengtsson BA, Eden S, Lonn L, et al. Treatment of adults with growth-hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 1993, 76, 309-317.
105. 105. Jorgensen J, Thuesen L, Muller J, Ovesen P, Skakkebaek NE, Christiansen JS. Three years of growth-hormone treatment in growth hormone-deficient adults - near normalization of body-composition and physical performance. Eur J Endocrinol 1994, 130, 224-228.
106. 106. Clark RG, Mortensen DL, Carlsson LMS, Carlsson B, Carmignac DF, Robinson ICAF. The obese GH-deficient dwarf rat: body fat responses to patterned delivery of GH and IGF-1. Endocrinology 1996, 137, 1904-1912.
107. 107. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homolog. Nature 1994, 372, 425-431.
108. 108. Tartaglia LA, Dembski M, Weng X, et al. Identification and expression cloning of a leptin receptor. OB-R. Cell 1995, 83, 1263-1271.
109. 109. Kupfer SR, Underwood LE, Baxter RC, Clemmons DR. Enhancement of the anabolic effects of growth-hormone and insulin-like growth factor-1 by use of both agents simultaneously. J Clin Invest 1993, 91, 391-396.
110. 110. Reiss K, Meggs LG, Li P, Olivetti G, Capasso JM, Anversa P. Up-regulation of IGF(1), IGF(1)-preceptor, and late growth-related genes in ventricular myocytes acutely after infarction in rats. J Cell Physiol 1994, 158, 160-168.
111. 111. Guan J, Williams C, Gunning M, Mallard C, Gluckman P. The effects of IGF-1 treatment after hypoxic-ischemic brain injury in adult-rats. J Cerebral Blood Flow Metab 1993, 13, 609-616.
112. 112. Beck KD, Powell-Braxton L, Widmer HR, Valverde J, Hefli F. IGF-1 gene disruption results in reduced brain size. CNS hypomyelination, and loss of hippocampal granule and striatal parvalbumin-containing neurons. Neuron 1995, 14, 717-730.
113. 113. Yao DL, Liu X, Hudson LD, Webster HD. Insulin-like growth factor I treatment reduces demyelination and upregulates gene expression of myelin-related proteins in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 1995, 92, 6190-6194.
114. 114. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 1995, 55, 249-252.
115. 115. Buckbinder L, Talbott R, Velasco-Miguel S, et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995, 377, 646-649.
116. 116. Angelloznicoud P, Binoux M. Autocrine regulation of cell-proliferation by the insulin-like growth-factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell-line (PC-3). Endocrinology 1995, 136, 5485-5492.
117. 117. Clark RG, Strasser J, McCabe S, Robbins K, Jardieu P. Insulin-like growth factor-1 stimulation of lymphopoiesis. J Clin Invest 1993, 92, 540-548.
118. 118. Jardieu P, Clark R, Mortensen D, Dorshkind K. In vivo administration of insulin-like growth-factor-1 stimulates primary B-lymphopoiesis and enhances lymphocyte recovery after bone-marrow transplantation. J Immunol 1994, 152, 4320-4327.
119. 119. Swisshelm K, Rvan K, Tsuchiya K, Sager R. Enhanced expression of an insulin growth factor-like binding protein (mac25) in senescent human mammary epithelial cells and induced expression with retinoic acid. Proc Natl Acad Sci USA 1995, 92, 4472-4476.
120. 120. Baxter RC, Martin JL, Beniac VA. High molecular weight insulin-like growth factor binding protein complex: purification and properties of the acid-labile subunit from human serum. J Biol Chem 1989, 264, 11843-11848.
121. 121. Clemmons DR. IGF binding proteins and their functions. Mol Reprod Dev 1993, 35, 368-375.
122. 122. Baxter RC. Holman SR, Corbould A, Stranks S, Ho PJ, Braund W. Regulation of the insulin-like growth factors and their binding proteins by glucocorticoids and growth hormone in nonislet cell tumour hypoglycaemia. J Clin Endocrinol Metab 1995, 80, 2700-2708.
123. 123. Soos MA, Field CE, Siddle K. Purified hybrid insulin insulin-like growth factor-1 receptors bind insulin-like growth factor-1, but not insulin, with high-affinity. Biochem J 1993, 290, 419-426.
124. 124. Thissen JP, JM K, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocrinol Rev 1994, 15, 80-101.
125. 125. Cox GN, McDermott MJ, Merkel E, et al. Recombinant human-insulin-like growth factor (IGF)-binding protein-1 inhibits somatic growth stimulated by IGF-1 and growth hormone in hypophysectomized rats. Endocrinology 1994, 135, 1913-1920.
126. 126. Dai Z, Xing Y, Boney CM, Clemmons DR. D'Ercole AJ. Human insulin-like growth factor-binding protein-1 (hIGFBP-1) in transgenic mice: characterization and insights into the regulation of IGFBP-1 expression. Endocrinology 1994, 135, 1316-1327.
127. 127. Rajkumar K, Barron D, Lewitt MS, Murphy LJ. Growth retardation and hyperglycemia in insulin-like growth factor binding protein-1 transgenic mice. Endocrinology 1995, 136, 4029-4034.
128. 128. De Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and the extracellular domain of its receptor: crystal structure of the complex. Science 1992, 255, 306-312.